Literature DB >> 16489040

Endocytic recycling compartments altered in cisplatin-resistant cancer cells.

Xing-Jie Liang1, Sushmita Mukherjee, Ding-Wu Shen, Frederick R Maxfield, Michael M Gottesman.   

Abstract

The clinical utility of cisplatin to treat human malignancies is often limited by the development of drug resistance. We have previously shown that cisplatin-resistant human KB adenocarcinoma cells that are cross-resistant to methotrexate and heavy metals have altered endocytic recycling. In this work, we tracked lipids in the endocytic recycling compartment (ERC) and found that the distribution of the ERC is altered in KB-CP.5 cells compared with parental KB-3-1 cells. A tightly clustered ERC is located near the nucleus in parental KB-3-1 cells but it appears loosely arranged and widely dispersed throughout the cytoplasm in KB-CP.5 cells. The altered distribution of the ERC in KB-CP.5 cells is related to the amount and distribution of stable detyrosinated microtubules (Glu-alpha-tubulin), as previously shown in Chinese hamster ovary B104-5 cells that carry a temperature-sensitive Glu-alpha-tubulin allele. In addition, B104-5 cells with a dispersed ERC under nonpermissive conditions were more resistant to cisplatin compared with B104-5 cells with a clustered ERC under permissive conditions. We conclude that resistance to cisplatin might be due, in part, to reduced uptake of cisplatin resulting from an endocytic defect reflecting defective formation of the ERC, possibly related to a shift in the relative amounts and distributions of stable microtubules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489040      PMCID: PMC1382193          DOI: 10.1158/0008-5472.CAN-05-3436

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

Authors:  P A Andrews; S B Howell
Journal:  Cancer Cells       Date:  1990-02

2.  Distinct populations of microtubules: tyrosinated and nontyrosinated alpha tubulin are distributed differently in vivo.

Authors:  G G Gundersen; M H Kalnoski; J C Bulinski
Journal:  Cell       Date:  1984-10       Impact factor: 41.582

Review 3.  Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).

Authors:  Gangduo Wang; Eddie Reed; Qingdi Q Li
Journal:  Oncol Rep       Date:  2004-11       Impact factor: 3.906

Review 4.  Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA.

Authors:  A L Pinto; S J Lippard
Journal:  Biochim Biophys Acta       Date:  1985

5.  Sphingolipid metabolism in cultured fibroblasts: microscopic and biochemical studies employing a fluorescent ceramide analogue.

Authors:  N G Lipsky; R E Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

6.  Turnover of the carboxy-terminal tyrosine of alpha-tubulin and means of reaching elevated levels of detyrosination in living cells.

Authors:  J Wehland; K Weber
Journal:  J Cell Sci       Date:  1987-09       Impact factor: 5.285

7.  Lipid recycling between the plasma membrane and intracellular compartments: transport and metabolism of fluorescent sphingomyelin analogues in cultured fibroblasts.

Authors:  M Koval; R E Pagano
Journal:  J Cell Biol       Date:  1989-06       Impact factor: 10.539

8.  Detyrosination of alpha tubulin does not stabilize microtubules in vivo.

Authors:  D R Webster; J Wehland; K Weber; G G Borisy
Journal:  J Cell Biol       Date:  1990-07       Impact factor: 10.539

9.  Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells.

Authors:  C R Hopkins; I S Trowbridge
Journal:  J Cell Biol       Date:  1983-08       Impact factor: 10.539

10.  Intracellular translocation of fluorescent sphingolipids in cultured fibroblasts: endogenously synthesized sphingomyelin and glucocerebroside analogues pass through the Golgi apparatus en route to the plasma membrane.

Authors:  N G Lipsky; R E Pagano
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

View more
  19 in total

1.  The chemical genomic portrait of yeast: uncovering a phenotype for all genes.

Authors:  Maureen E Hillenmeyer; Eula Fung; Jan Wildenhain; Sarah E Pierce; Shawn Hoon; William Lee; Michael Proctor; Robert P St Onge; Mike Tyers; Daphne Koller; Russ B Altman; Ronald W Davis; Corey Nislow; Guri Giaever
Journal:  Science       Date:  2008-04-18       Impact factor: 47.728

2.  Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis.

Authors:  Xing-Jie Liang; Huan Meng; Yingze Wang; Haiyong He; Jie Meng; Juan Lu; Paul C Wang; Yuliang Zhao; Xueyun Gao; Baoyun Sun; Chunying Chen; Genmei Xing; Dingwu Shen; Michael M Gottesman; Yan Wu; Jun-Jie Yin; Lee Jia
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

Review 3.  Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles.

Authors:  Chiranjeevi Peetla; Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2013-09-19       Impact factor: 15.470

4.  Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms.

Authors:  David J Stewart; Constance Johnson; Adriana Lopez; Bonnie Glisson; Jay M Rhee; B Nebiyou Bekele
Journal:  J Thorac Oncol       Date:  2010-11       Impact factor: 15.609

5.  Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.

Authors:  Brian G Blair; Christopher A Larson; Preston L Adams; Paolo B Abada; Catherine E Pesce; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2010-10-07       Impact factor: 4.436

6.  Cisplatin interaction with phosphatidylserine bilayer studied by solid-state NMR spectroscopy.

Authors:  Magnus Jensen; Morten Bjerring; Niels Chr Nielsen; Willy Nerdal
Journal:  J Biol Inorg Chem       Date:  2009-09-19       Impact factor: 3.358

7.  Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.

Authors:  Justin C Jagodinsky; Agnieszka Sulima; Yiqi Cao; Joanna E Poprawski; Burchelle N Blackman; John R Lloyd; Rolf E Swenson; Michael M Gottesman; Matthew D Hall
Journal:  J Biol Inorg Chem       Date:  2015-09-01       Impact factor: 3.358

8.  Fractal analysis and ionic dependence of endocytotic membrane activity of human breast cancer cells.

Authors:  Monika Krasowska; Zbigniew J Grzywna; Maria E Mycielska; Mustafa B A Djamgoz
Journal:  Eur Biophys J       Date:  2009-07-18       Impact factor: 1.733

9.  Involvement of vacuolar sequestration and active transport in tolerance of Saccharomyces cerevisiae to hop iso-alpha-acids.

Authors:  Lucie A Hazelwood; Michael C Walsh; Jack T Pronk; Jean-Marc Daran
Journal:  Appl Environ Microbiol       Date:  2009-11-13       Impact factor: 4.792

10.  SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism.

Authors:  Xing-Jie Liang; Toren Finkel; Ding-Wu Shen; Jun-Jie Yin; Adorjan Aszalos; Michael M Gottesman
Journal:  Mol Cancer Res       Date:  2008-08-22       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.